Solventum Q2 sales, adjusted EPS beat estimates; FY outlook lifted

Solventum

05/08/2026 21:22

Overview
U.S. MedTech firm's Q2 sales and adjusted EPS beat analyst expectations
Company raises full-year guidance for organic sales growth, adjusted EPS and free cash flow
Solventum to separate Health Information Systems business segment

Outlook
Solventum raises 2026 organic sales growth outlook to 2.5%-3.0%
Company lifts 2026 adjusted EPS guidance to $7.10-$7.20
Solventum now sees 2026 free cash flow at $200 mln-$300 mln

Result Drivers
ORGANIC SALES GROWTH - Co said Q2 organic sales rose 9.5%, driven by strong volume and product mix across all segments
TARIFF REFUND - Co said increases in GAAP and adjusted gross margin were driven by IEEPA tariff refund
ERP-TIMING BENEFIT - Co said advance orders placed ahead of ERP cutovers contributed to sales and adjusted operating income margin

Company press release: ID:nPn7C39gSa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 sales
Beat
$2.21 bln
$2.16 bln (11 Analysts)
Q2 Adjusted EPS
Beat
$2.55
$1.91 (11 Analysts)
Q2 EPS
 
$0.53
 
Q2 Net Income
 
$92 mln
 

Reuters Recommended Reads
Aug 5 - Zimmer Biomet tops quarterly estimates, lifts profit forecast on strong implant demand
Aug 5 - Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall
Aug 3 - KKR to take medical-equipment maker Integer Holdings private in $5.7 billion deal

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)